<div id="readability-page-1"><div id="article-body-3076348"><div><p><strong>Key Takeaways:</strong></p><ul><li>HUTCHMED (HCM, Financial) experiences a leadership shift as CEO Weiguo Su takes a health-related leave, with CFO Johnny Cheng stepping in as acting CEO.</li> <li>Analysts are optimistic, forecasting significant upside potential with an average price target of $22.28, representing a 38.33% increase from the current price.</li> <li>HUTCHMED holds an &#34;Outperform&#34; rating with a favorable GF Value estimation, indicating growth prospects for investors.</li></ul><h2>Leadership Transition at HUTCHMED</h2><p>In a noteworthy update, HUTCHMED (China) Ltd (HCM) has announced a temporary change in its leadership. Current CEO Weiguo Su is taking a leave of absence due to health concerns, creating an immediate opening that CFO Johnny Cheng will fill on an interim basis. Cheng will manage dual responsibilities as acting CEO while maintaining his CFO role. This adjustment comes as the company aims to ensure seamless operations during this transitional period.</p><h2>Wall Street Analysts Forecast</h2><p><img src="https://imageproxy.pbkrs.com/https://www.gurufocus.com/news/3076348/hcm-hutchmeds-ceo-weiguo-su-on-health-leave-cfo-johnny-cheng-steps-in?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://www.gurufocus.com/news/3076348/hcm-hutchmeds-ceo-weiguo-su-on-health-leave-cfo-johnny-cheng-steps-in"/></p><p>The outlook for HUTCHMED remains positive according to Wall Street analysts. With insights from 12 experts, the consensus one-year price target averages at $22.28, offering a promising potential upside of 38.33% from the current trading price of $16.11. Estimates range widely from a high of $40.40 to a low of $6.47, reflecting varied expectations based on market conditions and company performance. Investors looking for detailed projections can explore further on the HUTCHMED (China) Ltd (HCM, Financial) Forecast page.</p><h2>Analyst Recommendations</h2><p>HUTCHMED (China) Ltd (HCM, Financial) currently enjoys a consensus rating of &#34;Outperform,&#34; as reflected in the average brokerage recommendation score of 1.8 from 11 firms. On a scale where 1 represents a Strong Buy and 5 signals a Sell, this rating underscores analysts' confidence in the stock's potential. This favorable assessment suggests confidence in the company's strategic direction and market positioning.</p><h2>GF Value Estimation</h2><p>GuruFocus provides an estimate of the GF Value for HUTCHMED, projecting it to be $21.12 in one year. This estimation implies a potential 31.14% rise from the current price of $16.105. The GF Value is a critical metric, calculated by considering the historical trading multiples, past business growth, and future performance forecasts. For those interested in a deeper dive into the company's financials, the HUTCHMED (China) Ltd (HCM, Financial) Summary page offers comprehensive data.</p><ul><li>CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.</li> <li>Insider Cluster Buys: <span>Stocks that multiple company officers and directors have bought. </span></li> <li>Double Buys: Companies that both Gurus and Insiders are buying </li> <li>Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back. </li></ul></div></div></div>

00013

<p>HUTCHMED (HCM) is undergoing a leadership change as CEO Weiguo Su takes health leave, with CFO Johnny Cheng stepping in as acting CEO. Analysts are optimistic, projecting a 38.33% upside potential with an average price target of $22.28. The company holds an "Outperform" rating, reflecting confidence in its growth prospects. The GF Value estimation suggests a potential rise to $21.12 in one year, indicating strong market positioning and strategic direction for investors.</p>

HCM: HUTCHMED's CEO Weiguo Su on Health Leave, CFO Johnny Cheng Steps In